Abstract
Our data indicated that pegylated liposomal quercetin can significantly improve the solubility and bioavailability of quercetin and can be a potential application in the treatment of tumor.
Introduction
Quercetin, a naturally occurring flavonoid found in common foods like onions and apples, has long been recognized for its potent anticancer properties. In laboratory settings, it acts as a multi-targeted pharmacological agent, inhibiting glycolysis, slowing macromolecule synthesis, and triggering apoptosis in malignant cells. However, its clinical utility has been severely limited by its extreme hydrophobicity. Previous attempts to administer Quercetin required harmful solvents like DMSO, and the drug was cleared from the bloodstream almost immediately, preventing therapeutic concentrations from reaching solid tumors.
Methods and Materials
To overcome these delivery challenges, researchers developed Q-PEGL (pegylated liposomal quercetin). This formulation encapsulates Quercetin within tiny (~130 nm) lecithin and cholesterol bubbles coated in polyethylene glycol (PEG). The study evaluated Q-PEGL through:
- Pharmacokinetics: Tracking plasma and tissue distribution via High-Performance Liquid Chromatography (HPLC).
- In Vitro Assays: Measuring cell death (MTT) and cell cycle progression (flow cytometry) in CT26, LL/2, and H22 cancer lines.
- In Vivo Models: Testing efficacy in immunocompetent mice bearing colon, lung, and liver tumors.
- Mechanistic Studies: Analyzing HSP70 expression (RT-PCR) and tumor vascularization (CD31 staining).
Enhanced Bioavailability and Circulation
A critical breakthrough of the Q-PEGL system is the dramatic extension of Quercetin's circulation time. While free Quercetin (FQ) is cleared from plasma within 5 minutes, the pegylated liposomal form maintains therapeutic levels for approximately 2 hours—a 24-fold increase in residence time.
This extended half-life, combined with the "Enhanced Permeability and Retention" (EPR) effect, allows the 130 nm liposomes to selectively accumulate in the leaky vasculature of solid tumors while bypassing healthy tissues. HPLC confirmed that while FQ is found mostly in the liver and kidneys (organs of excretion), Q-PEGL shows high and sustained accumulation specifically within the tumor tissue.
Mechanisms of Action
The study identified two primary pathways through which Q-PEGL suppresses tumor growth:
- HSP70 Downregulation: Q-PEGL specifically inhibits the expression of Heat Shock Protein 70, a "stress protein" that tumors use to survive the stress of rapid growth and low oxygen.
- Anti-Angiogenesis: Treatment significantly reduced microvessel density within tumors, effectively starving the cancer by preventing it from building new blood vessels.
Key Results: Apoptosis and Tumor Suppression
Q-PEGL demonstrated significant dose-dependent tumor inhibition. In colon cancer models, a 50 mg/kg dose led to a 40% survival rate at 40 days, whereas all control subjects died within 30 days.
A hallmark of the treatment's efficacy is its ability to induce programmed cell death. Flow cytometry analysis showed that apoptotic populations increased from a baseline of 6.4% in controls to 51.8% after 60 hours of Q-PEGL exposure.
Conclusion
Pegylated liposomal Quercetin represents a significant advancement in flavonoid-based cancer therapy. By solving the solubility and rapid clearance issues of free Quercetin, Q-PEGL enables effective tumor targeting and significant growth suppression. While the treatment did not achieve total tumor eradication in these models, it provides a robust platform for future combination therapies and optimized clinical dosing schedules.
Summary updated